SCHEMBL2194693

SCHEMBL2194693

CCCCCCCCCCCCCCCCCC(O)OCC

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GPR84 Q9NQS5 7/20 0.45
SPHK1 Q9NYA1 2/20 0.45
FFAR1 O14842 2/20 0.45
LMNA P02545 2/20 0.44
OPRM1 P35372 1/20 0.42
CYP2D6 P10635 2/20 0.42
GMNN O75496 1/20 0.42
POLB P06746 1/20 0.42
THPO P40225 1/20 0.42
MTOR P42345 1/20 0.42
BLM P54132 1/20 0.42
KDM4E B2RXH2 1/20 0.42
TP53 P04637 1/20 0.42
CYP1A2 P05177 1/20 0.42
CYP3A4 P08684 1/20 0.42
MAPT P10636 1/20 0.42
CETP P11597 1/20 0.42
HTT P42858 1/20 0.42
UBE2N P61088 1/20 0.42
SMPD1 P17405 3/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10936368 1.00 GPR84 (0.45) GPR84SPHK1FFAR1LMNAOPRM1
SCHEMBL27679537 1.00 GPR84 (0.45) GPR84SPHK1FFAR1LMNAOPRM1
SCHEMBL11486624 1.00 GPR84 (0.45) GPR84SPHK1FFAR1LMNAOPRM1
SCHEMBL28133352 1.00 GPR84 (0.45) GPR84SPHK1FFAR1LMNAOPRM1
SCHEMBL9637168 1.00 GPR84 (0.45) GPR84SPHK1FFAR1LMNAOPRM1
SCHEMBL2197335 1.00 GPR84 (0.45) GPR84SPHK1FFAR1LMNAOPRM1
SCHEMBL23038706 1.00 GPR84 (0.45) GPR84SPHK1FFAR1LMNAOPRM1
SCHEMBL10941210 1.00 GPR84 (0.45) GPR84SPHK1FFAR1LMNAOPRM1
SCHEMBL9637167 1.00 GPR84 (0.45) GPR84SPHK1FFAR1LMNAOPRM1
SCHEMBL22444497 1.00 GPR84 (0.45) GPR84SPHK1FFAR1LMNAOPRM1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-111808011-B High penetration composition and its application 泰飞尔生物医药(苏州)有限公司 2024-02-27 CN disclosed
US-8485657-B2 Sublimation printing processes and fabric pretreatment compositions for ink jet printing onto arbitrary fabrics ADVANCED CHEMICAL SOLUTIONS, LLC (US) 2013-07-16 US disclosed
US-20110169901-A1 Sublimation Printing Processes and Fabric Pretreatment Compositions for Ink Jet Printing onto Arbitrary Fabrics ADVANCED CHEMICAL SOLUTIONS, LLC (US) 2011-07-14 US disclosed
US-20090220443-A1 COMPOSITIONS COMPRISING METATHESIZED UNSATURATED POLYOL ESTERS ELEVANCE RENEWABLE SCIENCES, INC. (US) 2009-09-03 US disclosed
EP-1188856-B1 Ink-jet printing method and printed goods SEIREN CO LTD (JP) 2005-11-16 EP disclosed
US-6623532-B2 Cellulose and synthetic fibers is treated with an acidic aqueous dispersion containing cellulose reactive compound, water soluble polymer, non-water soluble inactive organic compound, drying, ink-jet printing with reactive and disperse SEIREN CO., LTD. (JP) 2003-09-23 US disclosed
EP-1188856-A1 Ink-jet printing method and printed goods SEIREN CO., LTD. (JP) 2002-03-20 EP disclosed
US-20020025379-A1 Ink-jet printing method and printed goods SEIREN CO., LTD. 2002-02-28 US disclosed
EP-0746311-B1 MEDICINAL PATCHES FOR PERCUTANEOUS ADMINISTRATION PACIFIC CORP (KR) 2001-07-11 EP disclosed
EP-0746311-A1 MEDICINAL PATCHES FOR PERCUTANEOUS ADMINISTRATION PACIFIC CORPORATION (KR) 1996-12-11 EP disclosed
WO-1996019976-A1 MEDICINAL PATCHES FOR PERCUTANEOUS ADMINISTRATION PACIFIC CORPORATION (KR) 1996-07-04 WO disclosed
US-5505956-A TRANSDERMAL SKIN PATCH PACIFIC CHEMICAL CO., LTD. (KR) 1996-04-09 US disclosed
US-5470563-A Polyethersiloxane SHISEIDO COMPANY LTD. (JP) 1995-11-28 US disclosed
EP-0266921-A2 Skin irritation alleviation agent and composition thereof SHISEIDO COMPANY LIMITED (JP) 1988-05-11 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090220443-A1 COMPOSITIONS COMPRISING METATHESIZED UNSATURATED POLYOL ESTERS MGLL, SQLE, PHOSPHO1 GPR84 472/4885SPHK1 272/4885FFAR1 253/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.